Login to Your Account

Will data sway FDA decision?

Avastin Improves PFS Again in Phase III Breast Cancer Trial

By Trista Morrison

Thursday, February 14, 2008
A Phase III trial of Avastin (bevacizumab) in breast cancer met its primary endpoint of improving progression-free survival (PFS), but analysts remained split on whether the new data would be enough to gain FDA approval. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription